The Sell Rating in the Pitch Deck
You are the CCO of a boutique broker-dealer. An analyst covers industrial technology and has a Sell rating and a $30 target on Apex Corp., which trades at $38. The investment banking team is pitching Apex for a follow-on equity offering that would generate roughly $4 million in fees. Before Friday's pitch, the head of investment banking asks the analyst to (1) attend the meeting to 'show we know the story,' (2) pull the $30 target out of the model until after the pitch so the client is not offended, and (3) accept a revised bonus formula weighted 40% to investment banking revenue. The analyst is uncomfortable and comes to you.
1. Which of the three requests are permissible, and which are not?
Read the worked answer
Request 1 - pitch attendance: conditional. FINRA Rule 2241 prohibits investment banking personnel from directing the analyst's views and restricts the analyst's role in sales and marketing. Analyst participation in a pitch, if the firm's procedures permit it, should be about explaining coverage and research judgment. It must not become a solicitation, and the analyst must not be coached on what to say.
Request 2 - pulling the target: no. Review of research by investment banking personnel is limited to factual accuracy and legal issues. Editing or temporarily removing a rating or target because it might offend a prospective client is precisely the influence the rule forbids, and doing it around a live pitch makes it worse.
Request 3 - bonus formula: no. Analyst compensation may not be tied to specific investment banking transactions, and a heavy weighting to investment banking revenue is the same conflict in aggregate form. It would also make the analyst's independence impossible to defend in any later review.
Bottom line. Two of the three requests should be refused and the refusal documented. The third requires written parameters before the analyst attends anything.
2. What must you do as CCO before Friday, and what documentation should exist?
Read the worked answer
Before Friday.
- Respond in writing to the head of investment banking: the target stays in the model, the bonus proposal is rejected for now, and analyst attendance is permitted only within the firm's written pitch parameters.
- Brief the analyst that no one in investment banking may direct, pressure, or retaliate, and confirm she can decline to attend without consequence.
- Confirm an information barrier exists between the deal team and the analyst's work, including no sharing of draft research for anything other than factual review.
Documentation.
- The written exchange with the head of investment banking.
- The firm's Rule 2241 procedures covering pitch participation, review of research, and analyst compensation.
- Evidence of the information barrier - access controls and acknowledgments.
- The analyst's compensation plan showing it is not tied to specific transactions.
If the analyst attends, a principal should be present or receive a readout and note it.
3. Three weeks later the analyst is removed from Apex coverage and her bonus is cut. What now?
Read the worked answer
This looks like retaliation for independent research, which Rule 2241 explicitly prohibits, and it may also be a failure of the firm's supervision.
Immediate steps.
- Preserve all records - the pitch request, the analyst's communications, the coverage decision, and the compensation change - under a litigation hold.
- Escalate to senior management and, if the firm has one, to legal counsel outside the investment banking chain.
- Interview the decision-makers separately and require a written, non-research-related business rationale for the coverage change and the bonus reduction.
- Restore the analyst's compensation and coverage absent a legitimate, documented reason; consider interim reporting lines that remove investment banking from the decision.
Ongoing. Determine whether the conduct is a reportable event to FINRA and whether it requires disclosure on any associated person's Form U4. Then fix the structure: compensation and coverage decisions should be made by research management with compliance oversight, not by the revenue producers the research covers.